Skip to content
Sign in

NAGE · NASDAQ

Niagen Bioscience (NAGE) Stock Price & Fundamentals

$522.32+1.67%+$8.60End-of-day price as of Oct 9, 2026

Niagen Bioscience (NAGE) closed at $522.32 on Oct 9, 2026, up 1.67% from the previous close of $513.72.

Share price, past year

1Y −2.00%

52-week range $473.53 – $568.65. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$522.32
Sep 30, 2026$509.65
Aug 31, 2026$521.82
Jul 31, 2026$508.87
Jun 30, 2026$493.04
May 29, 2026$498.73
Apr 30, 2026$490.16
Mar 31, 2026$506.60
Feb 27, 2026$499.92
Jan 30, 2026$518.31
Dec 31, 2025$516.28
Nov 28, 2025$548.30
Oct 31, 2025$568.65

Key statistics

Market cap
$41.22B
P/E (TTM)
2,901.8
EPS (TTM)
$0.18
Revenue (TTM)
$129.08M
Net income (TTM)
$15.99M
Shares outstanding
78.9M
Dividend yield
—
52-week range
$473.53 – $568.65

Niagen Bioscience's market cap is $41.22B, based on a share price of $522.32 and 78.9M shares outstanding as of Jun 30, 2026.

Financials

Niagen Bioscience reported revenue of $129.42M for fiscal 2025, up 29.95% from fiscal 2024.

Niagen Bioscience earned net income of $17.38M in fiscal 2025, a net margin of 13.4%.

Fiscal 2025 revenue was the highest in the 10 years shown.

Annual revenue

FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
Niagen Bioscience annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Dec 31, 2025$129.42M+30.0%$17.38M13.4%$0.20—
FY2024ended Dec 31, 2024$99.60M+19.2%$8.55M8.6%$0.11—
FY2023ended Dec 31, 2023$83.57M+16.0%−$4.94M−5.9%−$0.07—
FY2022ended Dec 31, 2022$72.05M+6.8%−$16.54M−23.0%−$0.24—
FY2021ended Dec 31, 2021$67.45M+13.8%−$27.13M−40.2%−$0.40—
FY2020ended Dec 31, 2020$59.26M+28.0%−$19.93M−33.6%−$0.33—
FY2019ended Dec 31, 2019$46.29M+46.7%−$32.15M−69.5%−$0.56−$21.18M
FY2018ended Dec 31, 2018$31.56M+48.9%−$33.32M−105.6%−$0.61−$22.23M
FY2017ended Dec 30, 2017$21.20M−2.1%−$11.38M−53.7%−$0.26−$10.97M
FY2016ended Dec 31, 2016$21.66M—−$2.93M−13.5%−$0.08−$4.44M
Niagen Bioscience quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q2 FY2026ended Jun 30, 2026$29.79M$963.00K$0.01
Q1 FY2026ended Mar 31, 2026$31.47M$6.32M$0.07
Q4 FY2025ended Dec 31, 2025$33.84M$4.13M$0.05
Q3 FY2025ended Sep 30, 2025$33.99M$4.58M$0.05
Q2 FY2025ended Jun 30, 2025$31.12M$3.61M$0.04
Q1 FY2025ended Mar 31, 2025$30.48M$5.06M$0.06
Q4 FY2024ended Dec 31, 2024$29.13M$7.18M$0.10
Q3 FY2024ended Sep 30, 2024$25.58M$1.88M$0.02

Company profile

Name
Niagen Bioscience, Inc.
Ticker
NAGE
Exchange
NASDAQ
Industry (SEC SIC)
Medicinal Chemicals & Botanical Products
Headquarters
10900 Wilshire Blvd, Suite 600, Los Angeles, CA 90024
Incorporated in
DE
Fiscal year ends
December
SEC CIK
0001386570

Recent SEC filings

Frequently asked questions

What is Niagen Bioscience's stock price?

Niagen Bioscience (NAGE) closed at $522.32 on Oct 9, 2026, up 1.67% from the previous close of $513.72.

What is Niagen Bioscience's market cap?

Niagen Bioscience's market cap is $41.22B, based on a share price of $522.32 and 78.9M shares outstanding as of Jun 30, 2026.

How much revenue does Niagen Bioscience make?

Niagen Bioscience reported revenue of $129.42M for fiscal 2025, up 29.95% from fiscal 2024.

What is NAGE's P/E ratio?

Niagen Bioscience's price-to-earnings ratio is 2,901.8, based on trailing twelve-month diluted EPS of $0.18.

Does Niagen Bioscience pay a dividend?

Niagen Bioscience's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from Niagen Bioscience, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures